COFEPRIS alert on falsified sclerosis medicine

The Federal Commission for the Protection against Sanitary Risks (COFEPRIS) issued an alert about the counterfeiting of the drug Ocrevus, indicated for treating people with relapsing and primary progressive multiple sclerosis.

The detected product corresponds to batches B1018A01, H0531B59, and A3011Z02, which have expiration dates of June 2023, February 2023, and April 2022 and are not recognized by the manufacturer, Roche Laboratories.

They also present texts in English and incorrect QR code format.

Cofepris warned that its use represents a health risk, so it recommended that patients, medical personnel, and public health institutions review the products they have in their possession and those they will acquire.

The health agency also urged the population to go to formally established places to fill their prescriptions and avoid acquisition through social networks, street markets, or individuals who cannot prove their legal acquisition.

Source: La Jornada

The major issues for the further development of the pharmaceutical market will be discussed at the Mexican Pharmaceutical Forum that will be organized by the Global Pharmaceutical Leaders’ Club on the 29-30th November 2022 in Mexico City. Secure your delegate place ASAP! Registration is here:

Mexican Pharmaceutical Forum

No Comment.